- In April 2023, GSK plc announced positive Phase III trial results for its RSV vaccine candidate, Arexvy, targeted at older adults. The vaccine demonstrated strong efficacy in preventing RSV-related lower respiratory tract disease, marking a major advancement in protecting vulnerable populations. GSK’s development reflects the growing focus on preventive strategies for respiratory infections and the increasing role of vaccines in reducing healthcare burden globally.
- In March 2023, Pfizer Inc. launched Abrysvo, its bivalent RSV vaccine for adults aged 60 and above, following FDA approval. The dual-strain formulation is designed to provide broader protection against circulating RSV strains. The introduction of Abrysvo underscores Pfizer’s commitment to innovation in respiratory care and supports global efforts to combat seasonal and age-related viral infections
- In March 2023, Moderna Inc. announced promising interim results from its Phase III trial for mRNA-1010, a quadrivalent influenza vaccine based on mRNA technology. The candidate showed immunogenicity comparable to or better than existing licensed flu vaccines. This development signifies a potential shift toward mRNA-based platforms for seasonal viral infection prevention, leveraging the success of COVID-19 vaccine technology
- In February 2023, Roche Holding AG, through its diagnostics division, launched a next-generation multiplex PCR test capable of simultaneously detecting COVID-19, influenza A/B, and RSV. The new test enhances diagnostic efficiency and accuracy, particularly during respiratory infection surges, and supports clinicians in making faster, informed treatment decisions. The launch reflects the increasing emphasis on rapid diagnostics in viral disease management
- In January 2023, AstraZeneca and Sanofi received expanded regulatory approval in the EU for Beyfortus (nirsevimab), a long-acting monoclonal antibody for the prevention of RSV in infants. The approval allows a broader application beyond high-risk infants, marking a shift toward universal RSV prophylaxis. This collaborative innovation highlights the growing role of monoclonal antibodies in respiratory infection prevention and pediatric healthcare
